Lead Product(s) : Albendazole,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's Laboratories Announces the Launch of Albendazole Tablets, USP in the U.S. Market
Details : Albendazole Tablets, USP, a therapeutic equivalent generic version of Albenza Tablets, 200 mg, approved by the U.S. Food and Drug Administration. Dr. Reddy’s Albendazole Tablets, USP are available in 200 mg tablets in bottle count sizes of two.
Product Name : Albendazole-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 29, 2021
Lead Product(s) : Albendazole,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Albendazole,Inapplicable
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2024
Lead Product(s) : Albendazole,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Albendazole,Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Leiden University Medical Center | Bahir Dar University | Centro de Investigacao em Saude de Manhica | London School of Hygiene & Tropical Medicine | Kenya Medical Research Institute | Laboratorios Liconsa | Universidad de León | European & Developing Cou
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 18, 2021
Lead Product(s) : Albendazole,Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Leiden University Medical Center | Bahir Dar University | Centro de Investigacao em Saude de Manhica | London School of Hygiene & Tropical Medicine | Kenya Medical Research Institute | Laboratorios Liconsa | Universidad de León | European & Developing Cou
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Moxidectin,Albendazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2020
Lead Product(s) : Moxidectin,Albendazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Albendazole,Ivermectin,Azithromycin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Armauer Hansen Research Institute, Ethiopia | Federal Minstry of Health of Ethiopia
Deal Size : Inapplicable
Deal Type : Inapplicable
Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 27, 2018
Lead Product(s) : Albendazole,Ivermectin,Azithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Armauer Hansen Research Institute, Ethiopia | Federal Minstry of Health of Ethiopia
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Albendazole,Fortified Blend Flour,Azithromycin,Inulin,Fructo-Oligosaccharide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Action Contre la Faim | Centre de Recherches Médicales et Sanitaires CERMES Niger | Institut Pasteur de Madagascar | Institut Pasteur de Bangui | Institut Pasteur de Dakar
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2018
Lead Product(s) : Albendazole,Fortified Blend Flour,Azithromycin,Inulin,Fructo-Oligosaccharide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Action Contre la Faim | Centre de Recherches Médicales et Sanitaires CERMES Niger | Institut Pasteur de Madagascar | Institut Pasteur de Bangui | Institut Pasteur de Dakar
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IDA,Diethylcarbamazine,Albendazole,Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : The Task Force for Global Health | Murdoch Childrens Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 06, 2017
Lead Product(s) : IDA,Diethylcarbamazine,Albendazole,Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : The Task Force for Global Health | Murdoch Childrens Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ivermectin,Albendazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Ghana Health Service
Deal Size : Inapplicable
Deal Type : Inapplicable
Twice Yearly Treatment for the Control of LF
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 30, 2017
Lead Product(s) : Ivermectin,Albendazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Ghana Health Service
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Albendazole,Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Malaria Research and Training Center, Bamako, Mali | World Health Organization
Deal Size : Inapplicable
Deal Type : Inapplicable
Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 27, 2016
Lead Product(s) : Albendazole,Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Malaria Research and Training Center, Bamako, Mali | World Health Organization
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Albendazole,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam | Ho Chi Minh Preventive Medicine Centre, Vietnam | Princeton University | Cu Chi Health Department
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2015
Lead Product(s) : Albendazole,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam | Ho Chi Minh Preventive Medicine Centre, Vietnam | Princeton University | Cu Chi Health Department
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
